Host range, transmissibility and antigenicity of a pangolin coronavirus.

Host range, transmissibility and antigenicity of a pangolin coronavirus.

Publication date: Sep 25, 2023

The pathogenic and cross-species transmission potential of SARS-CoV-2-related coronaviruses (CoVs) remain poorly characterized. Here we recovered a wild-type pangolin (Pg) CoV GD strain including derivatives encoding reporter genes using reverse genetics. In primary human cells, PgCoV replicated efficiently but with reduced fitness and showed less efficient transmission via airborne route compared with SARS-CoV-2 in hamsters. PgCoV was potently inhibited by US Food and Drug Administration approved drugs, and neutralized by COVID-19 patient sera and SARS-CoV-2 therapeutic antibodies in vitro. A pan-Sarbecovirus antibody and SARS-CoV-2 S2P recombinant protein vaccine protected BALB/c mice from PgCoV infection. In K18-hACE2 mice, PgCoV infection caused severe clinical disease, but mice were protected by a SARS-CoV-2 human antibody. Efficient PgCoV replication in primary human cells and hACE2 mice, coupled with a capacity for airborne spread, highlights an emergence potential. However, low competitive fitness, pre-immune humans and the benefit of COVID-19 countermeasures should impede its ability to spread globally in human populations.

Open Access PDF

Concepts Keywords
Coronaviruses Airborne
Efficient Antibody
Genetics Cov
Mice Covid
Pangolin Efficient


Type Source Name
disease IDO host
disease VO efficient
disease MESH COVID-19
disease VO vaccine
disease MESH infection
disease IDO replication
disease VO USA
disease VO Viruses
disease IDO site
disease VO efficiency
disease MESH viral infection
disease VO viable
drug DRUGBANK Coenzyme M
pathway KEGG RNA polymerase
disease VO Glycoprotein
drug DRUGBANK Aspartame
drug DRUGBANK Proline

Original Article

(Visited 1 times, 1 visits today)